A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Avelumab (Primary) ; Regorafenib (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms REGOMUNE
- 05 Jun 2018 Trial design was presented at 54th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jun 2018 Status changed from not yet recruiting to recruiting.
- 26 Mar 2018 New trial record